- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06376851
Quantification des plaques dérivées de l'IA : CCTA et AI-QCPA pour déterminer une gestion efficace de la CAO (DECIDE)
Registre DECIDE : Quantification des plaques dérivées de l'IA : CCTA et AI-QCPA pour déterminer une gestion efficace de la CAO
The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The DECIDE Registry is a post-market, multi-center, data collection study assessing the change in management of clinically stable patients who undergo CCTA with plaque detected. Data will be retrospectively collected following the CCTA, and analyses will be completed 90 days, 180 days, and 1 year after CCTA. Data may be retrospectively collected annually up to 5 years.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
North Carolina
-
Greensboro, North Carolina, États-Unis, 27401
- Moses Cone Memorial Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Deidentified data will be collected for all patients who have had a CCTA with plaque detected or a stress test and are included by the site in the registry.
La description
Inclusion Criteria (all must be present) :
- Groups 1, 2,4,5 and 6: CCTA and plaque detected
- Group 3: Any patient with a stress test (stress echocardiogram or nuclear imaging including SPECT or PET) and no CCTA within the 90 days prior to site activation
- Groups 1,2,3 and 4: Clinically stable, symptomatic
- Group 6: Clinically stable without symptoms suggestive of CAD at the time of the CCTA
Exclusion Criteria (all must be absent) :
- ED presentation (at the time of the CCTA or stress test)
- Groups 1,2,3,4, and 6: Previous history of CAD (prior to the CCTA or stress test with history of revascularization)
- Group 5: Prior history of PCI in multiple vessel territories, PCI in the Left Main, CABG, and/or any other conditions or limitations which would prevent successful CCTA processing by HeartFlow
- Acute chest pain (in patients who have not been ruled out for ACS)
- Previously evaluated with and/or in a study which includes AI-QCPA
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: CROSS_SECTIONAL
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Group 1: No AI-QCPA
This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. No AI-QCPA will be provided. |
|
|
Group 2: Delayed AI-QCPA
This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. Ninety days following the CCTA, an AI-QCPA report will be provided to the CCTA reader who will in turn provide it to the treating clinician. The treating clinician will decide if changes to medical management are required to effectively treat the patient and if so, treating clinician will contact the patient with the new treatment plan. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
|
Group 3: Stress Test Only
This group includes symptomatic patients who previously had non-invasive stress testing only with no CCTA and no prior revascularization. No AI-QCPA will be provided. |
|
|
Group 4: Prospective AI-QCPA, symptomatic without prior revascularization
This group includes newly scanned, symptomatic patients with plaque detected and no prior revascularization. Patients in this group will have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
|
Group 5: Prospective AI-QCPA, prior PCI
This group includes newly scanned patients with plaque detected. Patients in this group can by symptomatic or asymptomatic and will have had prior PCI in only one vessel territory (CABG patients are not eligible). CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
|
Group 6: Prospective AI-QCPA, asymptomatic without prior revascularization
This group includes newly scanned, asymptomatic patients with plaque detected and no prior revascularization. Patients in this group will not have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient. |
The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary Endpoint
Délai: 90 Days
|
The primary endpoint of the DECIDE Registry is the change in medical management following HeartFlow AI-QCPA at 90 days compared to medical management following CCTA alone. The primary endpoint will only be assessed in patients in Group 2. |
90 Days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in LDL levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Change in HbA1c levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in Non HDL levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in HDL levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in TG levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Changes in weight
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups |
From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Reclassification rate of medical management (across the groups)
Délai: 90 Days, 180 Days and 365 Days
|
Change in preventive medical management (lower or intensify). |
90 Days, 180 Days and 365 Days
|
|
Rates of referral to invasive coronary angiography and coronary revascularization (PCI+CABG)
Délai: 90 Days, 180 Days and 365 Days
|
across the groups |
90 Days, 180 Days and 365 Days
|
|
Reclassification rate of symptoms
Délai: 90 Days, 180 Days and 365 Days
|
Improvement in symptoms across the groups |
90 Days, 180 Days and 365 Days
|
|
Number of CV hospitalizations
Délai: At 365 Days (and potentially out to 5 years)
|
across the groups |
At 365 Days (and potentially out to 5 years)
|
|
Number of Revascularizations
Délai: 365 Days
|
At one year across the groups |
365 Days
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of MACE (CV-related death, MI, or CAD hospitalization)
Délai: At 365 Days (and potentially out to 5 years)
|
Exploratory & safety endpoints will be compared across the groups unless otherwise noted |
At 365 Days (and potentially out to 5 years)
|
|
Timing of referral to other provider(s) for management
Délai: Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
across the groups unless otherwise noted |
Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
|
Timing of lab orders (Group 1 vs. Group 2)
Délai: Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
across the groups unless otherwise noted |
Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
|
|
Change in Lp(a) (Group 2)
Délai: Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups unless otherwise noted |
Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Change in Lp(a) (Group 4 compared to Group 1)
Délai: Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
across the groups unless otherwise noted |
Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
|
|
Rate of cardiac testing
Délai: At 365 Days (and potentially out to 5 years)
|
Efficiency of testing based upon imaging and reports for all other cardiac tests including CCTA, SPECT, echo, CAC, and stress echo |
At 365 Days (and potentially out to 5 years)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sarah Rinehart, MD, CAMC Health System
- Chercheur principal: Leslee Shaw, MD, MOUNT SINAI HOSPITAL
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CP-910-001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .